Petros Pharmaceuticals, Inc. Contracts & Agreements
37 Contracts & Agreements
- Business Finance (21 contracts)
- Business Operations (2)
- Human Resources (6)
- Intellectual Property (3)
- Uncategorized (5)
- Form of Amendment Agreement, dated November 13, 2024, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (Filed With SEC on November 13, 2024)
- Offer Letter Amendment, effective as of October 16, 2024, by and between the Company and Fady Boctor (Filed With SEC on October 18, 2024)
- Form of Amendment Agreement, dated October 11, 2024, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (Filed With SEC on October 17, 2024)
- Form of Omnibus Waiver and Amendment, dated March 21, 2024, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (Filed With SEC on March 22, 2024)
- First Amendment to Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (Filed With SEC on September 15, 2023)
- Form of Registration Rights Agreement (Filed With SEC on July 13, 2023)
- Form of Purchase Agreement (Filed With SEC on July 13, 2023)
- Form of Warrant (Filed With SEC on July 13, 2023)
- Amendment No. 1 to License and Commercialization Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on May 16, 2022)
- Settlement Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on May 16, 2022)
- Promissory Note, dated January 18, 2022, by Metuchen Pharmaceuticals LLC in favor or VIVUS LLC, a Delaware limited liability company (Filed With SEC on May 16, 2022)
- DESCRIPTION OF CAPITAL STOCK (Filed With SEC on March 31, 2022)
- Severance and General Release Agreement, dated March 1, 2022, between Andrew Gesek and Petros Pharmaceuticals, Inc., its affiliates, subsidiaries and successor entities (Filed With SEC on March 4, 2022)
- Amendment No. 1 to License and Commercialization Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
- Security Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
- Promissory Note, dated January 18, 2022, by Metuchen Pharmaceuticals LLC in favor or VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
- Settlement Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
- Form of Warrant (Filed With SEC on December 27, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on December 27, 2021)
- Second Amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (Filed With SEC on December 23, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on December 1, 2021)
- Form of Warrant (Filed With SEC on December 1, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on October 15, 2021)
- Form of Investor Warrant (Filed With SEC on October 15, 2021)
- Letter Agreement, dated as of March 31, 2021, by and between Metuchen Pharmaceuticals, LLC and Hybrid Medical LLC (Filed With SEC on April 6, 2021)
- Third Amendment to Loan and Security Agreement, dated as of September 30, 2020, by and between the Company, Pos-T-Vac, LLC, Timm Medical Technologies, LLC, the lenders a party... (Filed With SEC on March 31, 2021)
- Description of Capital Stock (Filed With SEC on March 31, 2021)
- Loan and Security Agreement, dated as of September 30, 2016, by and between the Company, the lenders a party thereto from time to time, and Hercules Capital, Inc (Filed With SEC on March 31, 2021)
- First Amendment to Loan and Security Agreement, dated as of November 22, 2017, by and between the Company, the lenders a party thereto from time to time, and Hercules Capital, Inc (Filed With SEC on March 31, 2021)
- Second Amendment to Loan and Security Agreement, dated as of April 13, 2020, by and between the Company, Pos-T-Vac, LLC, Timm Medical Technologies, LLC, the lenders a party... (Filed With SEC on March 31, 2021)
- License Agreement, dated as of March 14, 2020, by and between the Company and Hybrid Medical LLC (Filed With SEC on March 31, 2021)
- Letter Agreement, dated as of September 24, 2020, by and between the Company and Hybrid Medical LLC (Filed With SEC on March 31, 2021)
- Form of Petros Pharmaceuticals, Inc. Nonqualified Stock Option Grant Agreement (Filed With SEC on February 25, 2021)
- Employment Offer Letter, entered into as of February 19, 2021, by and between Petros Pharmaceuticals, Inc. and Fady Boctor (Filed With SEC on February 25, 2021)
- Separation Agreement, entered into as of December 24, 2020, by and between the Company and Keith Lavan (Filed With SEC on December 31, 2020)
- Bonus Agreement, entered into as of December 11, 2020, by and between Petros Pharmaceuticals, Inc. and Fady Boctor (Filed With SEC on December 15, 2020)
- Registration Rights Agreement, dated as of December 1, 2020, by and among Petros Pharmaceuticals, Inc. and JCP III SM AIV, L.P (Filed With SEC on December 2, 2020)
